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1. Introduction  
Tuberculosis (TB) continues to be one of the highest burdens and greatest challenges to 
public health. Annually, TB causes approximately 1.7 million deaths and 9.4 million incident 
cases worldwide. Although the incident rate of TB is slowly falling due to the expansion of 
the population, the absolute number of new TB cases is still increasing. It is estimated that 
two billion people (i.e., one-third of the global population) are infected with Mycobacterium 
tuberculosis (MTB), the causative agent of TB (World Health organization [WHO], 2009). 
MTB is one of the most successful human pathogens. Many efforts and resources have been 
invested to conquer this disease. Despite continuous efforts to generate effective strategies 
and approaches for prevention, control and treatment of TB, there has been little progress on 
developing vaccinations and drugs and increasing our understanding of the disease 
compared to the progression of the adaptability and pathogenicity of the pathogen, which 
is, even now, full of ambiguity regarding virulence factors and pathogenicity.  
Tuberculous meningitis (TBM), or TB meningitis, is the most devastating form of TB. The 
disease involves the infection of the meninges of the host, which is caused by MTB and 
other mycobacteria. This form of TB is of greatest concern due to its fatal outcome and 
neurological sequelae. The challenge is concentrated around rapid reliable diagnosis, 
treatment and understanding of its pathogenesis. The incidences of extrapulmonary TB and 
TBM are increasing (Kruijshaar et al., 2009). Drug resistance and HIV infection are the 
complications that make the treatment and management of TBM patients more difficult, and 
there are still doubts regarding many aspects of the disease. The lack of knowledge 
regarding TBM is challenging for us and other researchers. This review assembles, 
summarizes and discusses information regarding the epidemiology and drug resistance of 
TBM and the associations between MTB lineages and disease drawn from previous studies, 
along with information from studies that have been performed in Thailand. The overview of 
pathogenesis and the possible mechanism of TBM development are also discussed.  
www.intechopen.com
 
Meningitis 
 
86
1.1 Clinical features  
The cardinal clinical features of TBM include fever, anorexia and headache. Confusion is a 
late feature, and coma is a sign of poor prognosis. However, these features are not specific 
for TBM. The clinical features and outcome may vary depending on the delay of treatment, 
underlying disease, host immunity and virulence or lineage of MTB. The duration of the 
symptoms may vary from 1 day to 9 months. The common symptoms of TBM in terms of 
proportions of patients affected are fever (60–95%), anorexia (60–80%), headache (50–80%), 
vomiting (30–60%) and photophobia (5–10%). The clinical signs in terms of proportions of 
patients affected are neck stiffness (40–80%), coma (30–60%), any cranial nerve palsy (30–
50%), cranial nerve III palsy (5–15%), cranial nerve VI palsy (30–40%), cranial nerve VII 
palsy (10–20%), confusion (10–30%), hemiparesis (10–20%), paraparesis (5–10%) and 
seizures (children: 50%; adults: 5%) (Davis et al., 1993; Farinha et al., 2000; Girris et al., 1998; 
Hosoglu et al., 1998; Kent et al., 1993; Verdon et al, 1996; Thwaites et al., 2005a). The severity 
of TBM can be classified into three stages according to the patient's Glasgow coma score and 
the presence or absence of focal neurological signs by stage I: Alert and orientated without 
focal neurological deficit; stage II: Glasgow coma score (please see the following paragraph) 
14–10 with or without focal neurological deficit or Glasgow coma score 15 with focal 
neurological deficit; and stage III: Glasgow coma score less than 10, with or without focal 
neurological deficit (British Medical Research Council, 1948; Teasdale et al., 1974).  
Notably, the Glasgow coma score is scaled between 3 and 15, where 3 is the worst and 15 is 
the best. Three factors are assessed: best eye response (1=no eye opening, 2=eye opening to 
pain, 3=eye opening to verbal command, 4=eyes open spontaneously), best verbal response 
(1=no verbal response, 2=incomprehensible sounds, 3=inappropriate words, 4=confused, 
5=orientated), and best motor response (1=no motor response, 2=extension to pain, 
3=flexion to pain, 4=withdrawal from pain, 5=localizing pain, 6=obeys commands) (British 
Medical Research Council, 1948).  
1.2 Diagnosis 
The diagnosis of TBM is difficult because there are no specific clinical features and no rapid 
reliable tests. The problem of misdiagnosis and the delay of diagnosis subsequently lead to 
the delay of treatment and the reduction of the cure rate. The clinical criteria for 
differentiating TBM are essential. However, the prodrome is usually nonspecific, and the 
diagnosis cannot rely only on clinical signs. Due to the difficulty of diagnosis of TBM and 
the lack of effective diagnosis tools, there have been efforts to generate diagnosis rules for 
differentiating TBM from other meningitis diseases (Kumar et al, 1999). Confusion with 
other meningitis diseases (e.g., viral meningitis and other bacterial meningitis) is a problem 
for the diagnosis of TBM. This form of TB should be considered when a patient presents 
with meningoencephalitis, especially with pre-diagnosed TB or is a member of any high-risk 
groups (Leonard et al., 1990). For the TBM diagnostic test, it is important to perform a 
lumbar puncture; cerebrospinal fluid (CSF) can be examined by many tests (e.g., CSF AFB 
staining, CSF culture, CSF analysis of protein, glucose level, white blood cell count and 
detection of MTB complex nucleic acids and mycobacterium). The increase of protein and 
decrease of glucose with mononuclear cell pleocytosis are suspected indicators for TBM 
(Jeren & Beus, 1982). Radiographic assessments, such as computed tomography (CT) and 
magnetic resonance imaging (MRI), have vastly improved the identification of 
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complications of TBM (Bhargava et al., 1982; Bullock et al., 1982). The ideal features of a 
diagnostic test for TBM would require good sensitivity, specificity and more rapidity. Acid-
fast bacilli (AFB) staining from a direct specimen with careful and repeated searching for 
acid-fast bacilli (AFB) is still one of the most effective rapid diagnostic tests. However, AFB 
staining lacks sensitivity, though it is a common conventional detection method for 
pulmonary TB. The gold standard for definite diagnosis is based on the positive cultivation 
of mycobacteria from CSF. However, the culture results can be delayed and are often 
insufficient for aiding clinical diagnosis. There have been attempts to apply new rapid 
methods, such as molecular and immunological tests, to aid in the diagnosis of TBM 
(Kashyap et al., 2002; 2000; Mathai et al., 2001; Radhakrishnan et al, 1994; Robertson et al., 
1950; Srisaimanee et al., 2002; Sumi et al., 2002). Polymerase chain reaction is helpful for 
bacteriological confirmation. However, these new diagnostic methods have not been 
completely evaluated, and many tests require specific facilities and expertise. The diagnosis 
of TBM is still challenging and undoubtedly requires further approaches that are practical 
for use in all countries with improved reliability.  
1.3 Treatments and management of TBM 
Without appropriate treatment, TBM is a fatal disease with a high mortality rate. Many 
drugs used for the treatment of pulmonary TB have been used for the treatment of TBM as 
well. Nevertheless, there is much uncertainty regarding the treatment of TBM when 
compared to pulmonary TB (e.g., regimens, doses and the duration of chemotherapy). 
Streptomycin (SM) has been used for 60 years for TB treatment (Joint Tuberculosis 
Committee of the British Thoracic Society, 1998). The introductions of isoniazid (INH) and 
para-aminosalicylic acid (PAS) have provided further improvements in prognosis. A drug 
that can pass the blood-brain barrier (BBB) effectively can improve the efficacy of treatment. 
Rifampicin is 80% protein-bound in plasma; only 20% can penetrate the CSF in those with 
an intact BBB (Ellard et al., 1993). Nevertheless, the slow penetration of rifampicin through 
the BBB could allow its concentration in the CSF above the minimum inhibitory 
concentrations for MTB (Ellard et al., 1993). In contrast, INH, which is non-protein-bound, 
rapidly penetrates through the BBB in both healthy and inflamed conditions, which can 
yield concentrations > 30 times the MIC for MTB (Fletcher, 1953). The excellent capacity of 
pyrazinamide (PZA) to penetrate the BBB and its sterilizing activity against MTB makes this 
drug as a potential treatment for TBM (Humphries, 1992). Ethionamide penetrates healthy 
and inflamed meninges, but it can cause severe nausea and vomiting (Donald et al., 1989).  
Presently, treatment of TBM involves a combination of several anti-tuberculous drugs, as 
does treatment for pulmonary TB. The appropriate regimen of treatment recommends 
starting with INH, RIF and PZA. The addition of a fourth drug depends on the decision of 
the clinicians. The British Thoracic Society (BTS), the Infectious Diseases Society of America 
and the American Thoracic Society (IDSA/ATS) recommend a short-course of 
chemotherapy for the treatment of TBM, as is used for the treatment of pulmonary TB, with 
variations in duration: an “intensive phase” (2 months) of treatment with four drugs, 
followed by a “continuation phase” (6-9 months) with two drugs (BTS, 1998; Thwaites et al., 
2009a). The 6-month duration of treatment, as is used in pulmonary TB, could be used for 
TBM if the likelihood of drug resistance is low (van Loenhout-Rooyackers et al., 2001). 
Ethambutol and streptomycin are less effective for TBM treatment because of their poor 
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penetrating capacities and the adverse effect of optic neuritis. However, the BTS still 
recommends the use of these drugs as a choice for the fourth drug in the intensive phase. In 
cases of multidrug-resistant TBM (MDR-TBM), there are still no standard guidelines for 
chemotherapy (BTS, 1998; Thwaites et al., 2009a). Resistances to INH and RIF (MDR-TBM) 
are strong predictors of death (Thwaites et al., 2005b). MDR-TB isolates in Thailand were 
evaluated by their rpoB, katG and inhA genes; the results revealed relatively high numbers of 
mutations in amino acids 531, 526 and 516 of the rpoB gene, amino acid 315 of the katG gene 
and the promoter region of inhA (Boonaiam et al., 2010; Prammananan et al., 2008). 
Ethionamide, cycloserine, ofloxacin, and PAS could be used as second-line drugs based on 
the susceptibility profile of the infected strain or the data available in each country. 
Susceptible rates for ethionamide, ofloxacin and PAS in MDR-TB isolates from Thailand 
were 78.8%, 90.9%, and 85.9%, respectively (Prammananan et al., 2005; 2011). The molecular 
mechanism of ethionamide resistance in MDR-TB strains in Thailand was found to be 
partially related to a point mutation in the ethA gene in 54.1% of isolates (Boonaiam et al., 
2010). The appropriate duration of treatment for TBM is still controversial. The conventional 
duration for chemotherapy for TBM is 6-9 months (BTS, 1998; CDC, 2003). In young 
children, the 6-month duration can be used with high doses of anti-TB agents. Children 
must be treated for 12 months with a combination of antibiotic therapy and adjunctive 
corticosteroids.  
Systemic steroids may also be used, but the roles of steroids for TBM treatment are also in 
doubt, especially in HIV-infected patients. A finding from a drug trial study suggested that 
all TBM patients who are not infected with HIV should be given dexamethasone, regardless 
of age or disease severity (Thwaites et al., 2004). Adjuvant steroids may be used in the 
presence of increased intracranial pressure, altered consciousness, focal neurological 
findings, spinal block, and tuberculous encephalopathy. The benefit for using adjuvant 
corticosteroids for TBM patients involves reducing inflammation (Dooley et al., 1997; 
Humphries et al., 1992; Thwaites et al., 2004). In patients with obstructive hydrocephalus and 
neurological deterioration, placement of a ventricular drain or ventriculoperitoneal or 
ventriculo-atrial shunt should be performed. Prompt shunting improves outcome, 
particularly in patients with minimal neurological deficits. Additionally, surgical therapy 
for TBM patients can also be used in some cases, depending on the physician’s judgment.  
BCG vaccination has been debated concerning its capacity to protect against TB. The severe 
forms of TB, such as milliary TB and TBM in children, can probably be prevented by the 
BCG (Bacillus Calmette-Guérin) vaccine. Several studies have indicated the protective 
effects of the BCG vaccine against TBM (Awasthi and Moin, 1999; Puvacic et al., 2004; Mittal 
et al., 1996; Trunz et al., 2006; Xiong et al., 2009). A protective efficacy of approximately 60-
70% for the BCG vaccine against TBM has been reported (Thilothammal et al., 1996; 
Chavalittamrong et al., 1986). The study compared clinical presentations between BCG-
vaccinated and unvaccinated children and revealed that vaccinated TBM patients showed 
better mentation and had superior disease outcomes (Kumar et al., 2005). However, other 
studies have shown low protective effects of the BCG vaccine against TBM (Guler et al., 
1998; Tsenova et al., 2007; Wunsch Filho et al., 1990). More than 40% of TBM patients have 
been immunized with the BCG vaccine in Turkey (Hosoglu et al., 2003). The protective effect 
of the BCG vaccine against TBM in Thailand has been shown; though Thai people who have 
been immunized with the BCG vaccine still develop TBM, infected individuals are in a very 
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small proportion. Thailand has included mass immunization with the BCG vaccine for every 
newborn as the national public health policy since 1970. In Thailand, 76% of the protective 
effect of BCG against TB has been previously demonstrated, and a significantly lower 
extrapulmonary TB rate compared to pulmonary TB has also been demonstrated 
(Chavalittamrong et al., 1986). However, clear evidence of BCG vaccine efficacy against TB 
and extrapulmonary TB by experimental study is still required.  
2. Epidemiology of TBM 
Information on the epidemiology of TBM is fundamental for the prevention, treatment and 
control of the disease. Nevertheless, due to the difficulty of the collection of specimens from 
patients and its low incidence rate, TBM is a relatively rare form of TB for study. A large 
collection of patient samples (e.g., more than 100 samples) is even less affordable for study. 
Therefore, gathering study information is an easy way to obtain an overview of the available 
knowledge of TBM epidemiology.  
2.1 Incidence 
Human migration and the availability of air travel are the major factors that have distorted 
the human population structure, geographic distribution and spread of MTB. Nevertheless, 
associations between the human race in certain regions and specific lineages of MTB have 
still been observed (Gagneux et al., 2006). In 1997, TBM was the fifth most common form of 
extrapulmonary TB (WHO, 1997). From all TB cases, 90-95% of infected cases only have 
asymptomatic latent TB, whereas 5-10% of individuals (8-9 million people) have developed 
active disease, accounting for approximately 2 million deaths annually. The most common 
form of the disease is pulmonary TB, which has been estimated to represent 80% of all TB 
cases. Apart from the 20% of extrapulmonary TB cases, TBM has been calculated to 
represent 5.2% of extrapulmonary TB (WHO, 2009). The incidence of TBM from all reported 
TB cases is 0.7%. The incidence of central nervous system (CNS) TB is related to the 
prevalence of TB in the community. In countries with a high burden of pulmonary TB, the 
incidence of extrapulmonary TB and TBM are expected to be proportionately high. The 
incidence of TBM in the United States has been calculated to represent approximately 4.5% 
and 4.7% of total extrapulmonary TB cases in 1969-1973 and 1975-1990, respectively. From 
all samples that were sent to Siriraj Hospital in Bangkok, Thailand, for TB identification 
during 2000-2007, approximately 15% were CSF samples, 10% of which contained MTB and 
were identified as TBM. 
2.2 Mortality rate  
TBM is the most severe form of TB that involves the central nervous system. The mortality 
rate ranges from 20-60%, with an average of approximately 35% (table 1). Neurological 
sequelae can be found in approximately 25% of surviving patients (Hosoglu et al., 2002). It is 
not clear whether HIV infection is associated with TBM outcome. The summarized data 
indicate that the high mortality rate of TBM in South Africa from both studies is associated 
with a high proportion of HIV-infected cases, whereas no such associations were found in 
Thailand or France (table 1). Conflicts of such associations have been found in previous 
studies (Katrak et al., 2000; Thwaites et al., 2005a). However, HIV infection seems to be the 
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strongest factor that predisposes an individual to development of TBM. The mortality rate 
of TBM is different among countries, which may involve differences in medical personnel, 
management and facilities.  
Authors 
Countries of 
study 
Year 
Mean 
(range) 
age (yrs)
Gender
(% M/F)
HIV-
infected 
(number/%) 
Morta-
lity 
rate (%) 
1. Faksri et al., 2011a 
and Yorsangsukkamol 
et al., 2009  
Thailand (n=184)
1996-
2007 
33.6  
(0.25-83)
64/36 
48/72 
(66.7%) 
25 
2. Roca et al., 2008  Spain (n=29) 
1991-
2005 
34 (17-78) 59/41 15/29 (52%) 41 
3. Nagarathna et al., 
2007  
Egypt (n=336) 
2001-
2005 
NA  
(13-50) 
68/32 
48/107 
(44.9%) 
NA 
4. Thwaites et al. 2005a Vietnam (n=545)
2001-
2003 
33 (15-88) 72/28 
96/528 
(18.2%) 
30 
5. Patel et al., 2004  
South Africa 
(n=30) 
1999-
2002 
25.7 
(0.4-45) 
30/70 18/30 (60%) 56 
6. Sutlas et al., 2003  Turkey (n=61) 
1988-
2000 
34.5 
(16-74) 
64/36 NA 27.8 
7. Kalita and Misra, 
1999  
India (n=58) 
1992-
1996 
25.6 (1-64) 69/31 NA 20.6 
8. Hosuglo et al., 1998  Turkey (n=101) 
1985-
1996 
30.6  
(14-67) 
60/40 NA 43.5 
9. Karstaedt et al., 1998 
South Africa 
(n=56) 
1994-
1997 
33.5  
(18-59) 
53/47 
39/56 
(69.6%) 
69.6 
10. Verdon et al., 1996  France (n=48) 
1982-
1993 
46 (18-83) 67/33 
10/32 
(31.25%) 
64.5 
11. Davis et. al., 1993  
United States 
(n=54) 
1970-
1990 
NA (4-86) NA NA 23 
Note: NA= data not available, M=male, F= Female, HIV=human immunodeficiency virus 
Table 1. Epidemiological information of TBM patients from previous studies 
2.3 Predisposing risk factors  
The strongest risk factors for developing TBM are immunological status (e.g., HIV infection) 
and pre-diagnosed TB. Ages and genders of TBM patients also affect predisposition for TBM 
development. Prior to the predomination of HIV, the age of the patient was the most 
important factor leading to the development of TBM. The ages of TBM patients are different 
from pulmonary and other extrapulmonary TB diseases; TBM is commonly found in 
children ages 0-5 years (Farer and Meador, 1979). In populations with a low prevalence of 
TB, most cases of TBM occur in adults. In general, TBM is more common in children than in 
adults. Notably, the young ages of children are not always the most prevalent risk factors 
for TBM in all populations with high TB burdens, which might result from worldwide BCG 
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vaccination. For instance, in the Thai population, the most predominant ages of TBM 
patients are 31-45 years (35.3%), and only 12% of TBM patients are less than 15 years old 
(Yorsangsukkamol et al., 2009). With BCG vaccination, a significantly lower incidence of 
disseminated TB, such as TBM, was found in patients less than 12 years old compared to 
pulmonary TB (Chavalittamrong et al., 1986). The average ages of TBM patients in particular 
regions, even on different continents, are around 30 years higher (table 1). This evidence 
supports the idea that the HIV epidemic has increased the risk for adult TBM in the last 
three decades. In general, young children are more likely to develop meningeal or 
disseminated TB, whereas adolescents more frequently present with pleural or peritoneal 
TB compared to adults.  
Patient gender is also a predisposing factor for TBM development. Incidence is consistently 
higher for men than for women, with a ratio around 2:1. The proportion of affected females 
is slightly lower than that of males in the overall world population. However, the 2:1 ratio 
between male and female TBM patients has been found consistently in many countries. In 
children with TBM, the ratios between males and females are less affected. In Thailand, a 
male/female TBM patient ratio of 3:2 has been conserved over three periods of four-year 
intervals (Faksri et al., 2011a). The effect of gender on TBM development may be explained 
by socio-economic or anatomical-physiological factors.  
Co-infection with HIV and MTB, especially in AIDS patients, is also the strongest risk factor 
for progression to active TB. Compared to non-HIV-infected individuals, who have a 5-10% 
risk of developing active TB, HIV increases the risk of developing clinical TB post-infection 
to 1 in 3 individuals (Selwyn and Lewis, 1989). Furthermore, HIV also increases the 
possibility of developing extrapulmonary TB, especially TBM (Bishburg et al., 1986). The 
increase in TBM incidence is most likely due to an increased incidence of CNS-TB among 
patients with HIV/AIDS and to the increasing incidence of TB among infants, children and 
young adults. Cell-mediated immunity is the most important defense against TB infection, 
and a decline of CD4 T cells is associated with the development of TBM (De Cock et al., 
1992). Although patients who have HIV infection and TB are at increased risk for TBM, the 
effects of HIV infection on the clinical features and outcomes of TB are still disputed 
(Berenguer et al., 1992). Several studies that have assessed the effects of HIV infection on the 
clinical presentation of TBM have identified conflicting findings. HIV-infected patients may 
have altered clinical presentations, such as in pathological features, CSF parameters, 
frequency of infection with MDR-TB and mortality. Hospital-associated mortality was 
significantly higher in HIV-infected patients (Cecchini et al., 2009; van der Weert et al., 2006; 
Katrak et al., 2000; Bandyopadhyay et al., 2009). Other studies have found that HIV infection 
was not associated with mortality rate or altered neurological presentation in TBM, though 
additional extrapulmonary TB was more likely to occur in HIV-infected patients and may 
have also affected the survival rate (Faksri et al., 2011a; Thwaites et al., 2005a).  
Another important risk factor is pre-diagnosed TB. The most often associated form is 
milliary TB on chest x-rays, which presents as a disseminated form of TB with small 1- to 2-
mm lesions spreading in a large area of the lung and/or other organs. The development of 
TBM can consist of either the primary infection with a short incubation or a secondary 
reactivation of pulmonary TB with a long latent period.  
Previous studies using the tuberculin conversion rate have shown that black-skinned people 
are more susceptible to TB infection than are white-skinned people (Stead et al., 1990). 
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Consequently, the development of TBM may associate with certain host groups. The most 
striking study of host variation and TB is from Gagneux et al., which showed that the 
lineages of MTB are associated with certain geographical regions and ethnic groups from the 
patients’ countries of origin: the East Asian (Beijing) lineage predominates in patients from 
East Asia, whereas the Euro-American lineage mostly infects European people (Gagneux et 
al., 2006). Certain lineages of MTB are predominant in certain geographical regions and 
ethnic groups that are associated with TBM. Therefore, environmental factors (i.e., 
geographical region and race) also predispose individuals to develop TBM. More discussion 
on host variation and predisposing factors follows in sub-topic 5.2: “Host variation and 
development of TBM”.  
Other risk factors that may be involved in TBM development include: diabetes mellitus 
(Bernard-Griffiths et al., 1959; Pablos-Mendez and Knirsch, 1997), malignancy, malnutrition, 
alcoholism, head trauma (Davis and Lambert, 1993) and recent corticosteroid use (Mori and 
Welty, 1992). 
3. Overview of the pathogenesis of TBM 
A pathological view of TBM was first described in 1836 (Green, 1836). Then, in 1882, Robert 
Koch demonstrated that TB was caused by MTB (Koch, 1882). In 1912, a pathological 
experimental infection of TBM in an animal model was demonstrated (Manwaring, 1912). 
Subsequently, there have been several studies focused on the pathogenesis of TBM using 
animal experiments, in which a rabbit model is commonly used, as mice do not provide 
similar pathological characteristics to human TBM (Behar et al., 1963; Matsubara, 1956; 
Sidel'Nikova and Rozina, 1956; Tsenova et al. 2005; 2007; van Well et al., 2007).  
For an overview of pathogenesis (Figure 1), MTB infection occurs through the inhalation of 
aerosol droplets containing the bacilli. Only small droplets (1-5 µm in diameter) can reach 
and eventually deposit in the alveoli of the lungs. Inside the alveoli, the bacilli are engulfed 
by alveolar macrophages. Because MTB can survive in this hostile environment, the bacteria 
can infect and grow inside the macrophages ex vivo. Once these immune cells are triggered, 
numerous cytokines and chemokines are released. The activation of a Th1 cell-mediated 
immune response, the critical defense mechanism that plays a major role against MTB 
infection, occurs; ultimately, a granuloma, mainly composed of macrophage-derived giant 
cells and lymphocytes, is formed. In latent tuberculosis cases, the granuloma functions to 
contain the bacilli and is maintained depending on the strength of the host cellular immune 
response. Furthermore, the interaction between immune factors in the host and virulence 
factors in the pathogen may determine whether the infection will be restricted or 
disseminated and progressed into the next stage of the disease. Before the bacilli can gain 
access to the brain, spreading outside of the lung into the blood circulation is the critical step 
for extrapulmonary TB, a step that is poorly understood. The transportation of infected 
alveolar macrophages into the blood circulation is a current hypothesis for extrapulmonary 
spread. However, the discovery that MTB hematogenous dissemination is dependent on 
heparin-binding hemagglutinin adhesin, a bacterial virulence factor that interacts with 
epithelial cells, has suggested that other trafficking pathways may be important (Pethe et al., 
2001). The failure of immune responses from the host, along with virulence factors from the 
pathogen that promote a high capacity for evading immune responses (which may 
determine by lineages), are the factors that promote extrapulmonary spreading. 
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Fig. 1. Pathogenesis of TBM and postulation of the formation of Rich foci. (a) Aerosol 
transmission of MTB, (http://www.graphicshunt.com/health/ images/alveoli-268.htm)  
(b) Phagocytosis of MTB by alveolar macrophages inside alveoli. (c) Granuloma formation 
in the lung, which subsequently occurs due to cellular and cytokine network responses; 90% 
of hosts with granulomas maintain them stably over the course of their lives. (d) MTB 
escapes from the granuloma, which occurs in 10% of latent TB patients. (e) MTB can cause 
TBM by escalating from the lung or by secondary reactivation from a “leaked granuloma”, 
which is then filtered into a regional lymph node. (http://www.graphicshunt.com/health/ 
images/alveoli-268.htm) (f) After spreading through the blood circulation, MTB can enter 
the CNS through the BBB, likely by a Trojan horse mechanism. (g) Bacilli seed to the 
meninges or the brain parenchyma, forming subpial or sub-ependymal primary complexes, 
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termed “Rich foci”. (h) Rich foci increase in size, rupture and discharge into the 
subarachnoid space, which indicates the onset of TBM. (http://digitalunion.osu.edu/r2/ 
summer08/dzeleznikar/anatomy.html). Some part of figures (a, e, h) were modified from 
online sources as described. 
For TBM, the process of pathogenesis can be divided into two steps (Rich, 1993). First, the 
bacilli are filtered and disseminated into the draining lymph nodes. During this stage, there is 
a short but significant bacteremia that can seed the bacilli into other organs. Hematogenous 
spreading occurs most frequently in regions of the body that are highly oxygenated, including 
the brain. The pathogenesis of TBM might occur from a primary infection of MTB and develop 
into TBM directly or might be derived from the reactivation of pulmonary TB that 
subsequently develops into TBM (figure 1). Like other bacterial meningitis diseases, a 
prerequisite step of the pathological mechanism of TBM is the movement of the bacilli through 
the BBB (Kim et al., 2008). The factors that contribute to this movement remain unknown. The 
process may be a multifactorial process involving host–pathogen interactions. The bacilli can 
cross the BBB using both transcellular and paracellular mechanisms; alternatively, infected 
phagocytes may transmigrate via a so-called Trojan horse mechanism (Kim et al., 2008). 
Consequently, the pathogen can cause BBB dysfunction by inducing injury to the 
endothelium, resulting in an increase in permeability, pleocytosis and encephalopathy. For 
TBM, the Trojan horse mechanism seems to be the most possible strategy for traversal, as MTB 
is an intracellular pathogen and primarily infects macrophages; including a mechanism in 
which the bacilli, by themselves, evade the host immune responses and reach the brain would 
be difficult. However, transcellular penetration of the BBB has also been demonstrated for this 
pathogen (Jain et al., 2007). In addition, the factors that determine the fate of bacilli for 
hematogenous dissemination and development of TBM include the capacity to survive and 
replicate inside macrophages. Furthermore, the capacity of bacilli to reduce the occurrence of 
programmed cell death, which would reduce the viability of bacilli, may also be involved in 
the process of TBM pathogenesis. In those who develop TBM, bacilli seed to the meninges or 
the brain parenchyma, forming subpial or sub-ependymal primary complexes, termed “Rich 
foci” (Rich, 1993). This step, which has not yet been defined, may also determine the progress 
of the disease by both pathogen and host factors. In the second step, in approximately 10% of 
the cases that develop such complexes, particularly in children and immunocompromised 
hosts, the primary complex does not heal but progresses. This event can occur months or years 
after the formation of Rich foci (Rich, 1993; Thwaites and Schoeman, 2008). The location of the 
Rich foci determines the type of CNS involvement. In TBM, the Rich foci increase in size until 
they rupture and discharge into the subarachnoid space, which indicates the onset of TBM. 
The following processes can also take place: adhesions around the interpeduncular fossa can 
lead to CN palsies; adhesive exudates can obstruct CSF, leading to hydrocephalus; and 
obliterative vasculitis can lead to infarction. Encephalitis and tuberculomas can also occur. 
Rich foci located deeper in the brain or the spinal cord parenchyma can cause tuberculomas or 
abscesses. Notably, abscesses or hematomas can rupture into the ventricle, but not in the case 
of Rich foci (Rich, 1993). After the rupture of Rich foci, the bacilli and numerous leukocytes are 
released into the subarachnoid space. Then, the local T-cell-dependent response is activated. 
The subsequent necrotizing granulomatous and inflammatory responses are the result of the 
pathological events of TBM.  
On the cellular scale of TBM pathogenesis, the cytokines and chemokines that are 
consequently released from the host cellular response are thought to be important factors of 
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pathogenesis. Most of the symptoms, signs, and sequelae of TBM are the result of an 
immunological inflammatory reaction to the infection. Tumor necrosis factor-alpha TNF-α) is 
the key cytokine in the inflammatory response and is the critical cytokine in the 
neuropathogenesis of MTB (Mastroianni et al., 1997; Tsenova et al., 1999). Evidence has 
indicated a direct correlation between the level of this cytokine in the CSF and the progression 
of the pathogenesis of TBM (Tsenova et al., 1999). Also, TNF-α is a major determinant of 
disease in a rabbit model of meningitis (Tsenova et al., 2005). TNF-α also benefits the host by 
playing an important role in granuloma formation (Kaneko et al., 1999). These conflicting roles 
of TNF-α might depend on which polarity of cytokine responses (i.e., Th1 or Th2) dominate. 
Metalloproteinase-9 (MMP-9) is another cytokine that may play an important role in TBM 
pathogenesis by increasing the degradation of the BBB, which results in an increase in its 
permeability. Evidence has demonstrated that different genotypes of MTB can induce different 
host immune responses (Chaves et al., 1997, Yorsangsukkamol et al., 2011). 
Alternatively, host genetic polymorphisms can also affect their susceptibility for developing 
disease. Some cytokines and proteins that are released from host cells, such as TNF-α, are 
related to the development and pathogenesis of TBM. In TB, a strong Th1-like immunity is 
considered important for containment of mycobacteria. The major immune effector 
mechanism involved in the activation of infected macrophages is stimulated by Th1-type 
cytokines (Seth and Sharma, 2002). The protective effects of Th1-type cytokines can be 
antagonized by Th2-type cytokines (Manca et al., 2001), and increased production of Th2-
type cytokines may be responsible for the characteristic immunopathology of the disease. A 
balance between the Th1- and Th2-type cytokine responses in TB may influence 
mycobacterial growth, immunopathology and the fate of the disease (Seth and Sharma, 
2002). In addition, regarding the cytokine response, inflammatory cytokines are also 
determinants of immunopathology. The pathogenesis and virulence of the pathogen can 
also be determined by the balance between pro-inflammatory and anti-inflammatory 
cytokines.  
It remains unclear why only some individuals develop disseminated TB that spreads to the 
meninges and then the central nervous system, while most people suffer only localized 
disease in the lung. Important factors include HIV infection and younger patient age. This 
may indicate that the host immune response is a major factor that plays a role in the 
development of TBM. Apart from socio-economic and environmental factors, pathogen and 
host factors are considered to be more important in the development of TBM. However, it is 
not yet known which factors are the most important. Although it seems to be a 
multifactorial process, a number of studies have recently demonstrated that not only 
pathogen factors but also host factors could influence the development of TBM (Takahashi et 
al., 2005; Thuong et al., 2007; 2008). Studies have demonstrated that genetic polymorphism of 
Toll-interleukin 1 receptor domain-containing adaptive protein (TRAP-MAL) and Toll-like 
receptor 2 (TLR2) are associated with the susceptibility for developing TBM (Hawn et al., 
2006; Thuong et al., 2007). Gene expression profiles of human monocyte-derived 
macrophages (MDMs) have demonstrated that certain genetic variations, especially 
chemokine (C-C motif) ligand 1 (CCL1), could predispose an individual to develop a 
particular disease phenotype (i.e., pulmonary or latent TB, or TBM) (Thuong et al., 2008). 
Furthermore, Caws et al. demonstrated that particular mycobacterial genotypes (East Asian 
and Euro-American lineage) identified by large sequence polymorphisms (LSPs) and host 
genetic polymorphisms in TLR2 influence the development of TBM (Caws et al., 2008). A 
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study of the capacity of the HN878 Beijing strain to cause TB meningitis in a rabbit model 
revealed that a disruption of the pks15/1 gene that encodes a polyketide synthase-derived 
phenolic glycolipid (PGL) reduced virulence (Tsenova et al., 2005). However, pks15/1 is not a 
unique property of the Beijing lineage of MTB (Chaiprasert et al., 2006). Despite these 
findings, however, the pathogen virulence and host genetic polymorphism factors 
governing the development of TBM are still unclear. 
4. Anti-tuberculous drug resistance in TBM 
Many decades ago, TB was considered an incurable, deadly disease. With the availability of 
effective treatments, TB can now be cured. However, the complete treatment requires several 
months to stabilize the patient’s condition and to prevent the reoccurrence of disease. Pan-
drug-resistant (PDR) TB strains are now a new emerging and serious public health problem. 
Although the incidence of PDR-TB is not yet high, we cannot underestimate the adaptability of 
MTB, a highly successful human pathogen. In addition, the TB burden dominates in low- and 
middle-income countries (LMIC) where the drug susceptibility test is not fully available. The 
real prevalence of drug-resistant TB may therefore be markedly higher than the estimation. 
Furthermore, extensively drug-resistant (XDR) TB, which is more expensive and more difficult 
to treat than multidrug-resistant (MDR) TB, has more serious adverse effects, and the 
outcomes for patients are much worse. Despite the fact that there are several novel anti-
tuberculous drugs that have been developed and discovered recently, the levels of drug-
resistant TB, especially MDR- and XDR-TB (and PDR-TB), are still increasing. It is very 
threatening to consider the imbalance between the effective anti-tuberculous drugs and drug-
resistant TB, especially with the outbreak of MDR-TB in large areas. The most effective way to 
eradicate TB is with effective vaccination and control of latent TB. However, we are still 
struggling to find ways to beat this pathogen. For now, treatments for drug-resistant TB are 
still where we must focus. Yet, PDR-TB and TB with resistance to new drugs should be 
surveyed and monitored worldwide (Prammananan et al., 2006). The real hope lies with 
continuing to develop novel, effective anti-tuberculous drugs and vaccines.  
In TBM, drug resistance and HIV infection constitute additional conditions that make the 
treatment of patients become more complex and difficult. The diagnosis, treatment and 
management of these patients are major challenges. The delay of diagnosis and treatment of 
TBM can cause the subsequent deaths of patients. Therefore, drug-resistant TBM is a major 
issue of concern for the treatment and management of TBM.  
From data collected on TB cases from 81 countries between 2002 and 2006, the WHO 
reported that the incidence of pulmonary MDR-TB was approximately 4.8%. The highest 
numbers of MDR-TB were found in China, India, and the Russian Federation (WHO, 2008). 
In 2009, 3.3% of all new TB cases had MDR-TB (WHO, 2009). Unfortunately, information on 
the drug resistance of TBM from these countries was not available for this review. Studies 
on the drug resistance of TBM are relatively rare. From the data available, the drug-
resistance patterns for TBM were obtained from four countries: Thailand, Egypt, Vietnam 
and South Africa. Information gathered from previous studies found that the average 
incidence of TBM that was resistant to any drug was approximately 21.5% (with a range of 
12-31%). MDR-TBM was found in 2.2 to 8.6% of cases, with an average of approximately 
3.3% (table 2). The incidence of MDR-TBM was up to 18% in pediatric cases, with a 
mortality rate of 100%. Nevertheless, the sample size from this study was only 20 cases 
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(Chander, 2008). Resistance to particular anti-tuberculous drugs, such as isoniazid, 
represented the most resistant MTB strains in four out of five studies in the available data 
(table 2). Isoniazid resistance in TBM has been suggested to correlate with HIV co-infection 
(Thwaites et al., 2002). The second most-resistant drug is streptomycin. TBM showed 
minimal resistance to rifampicin (which can partially penetrate an intact BBB) and 
ethambutol. There was no evidence to support an increase in penetration capacity through 
the BBB for rifampicin after inflammation (Nau et al., 1992). The information in this review 
may support the idea that rifampicin is a good drug for effective treatment of TBM, with a 
lower chance of development of drug-resistant TBM, compared to isoniazid and 
streptomycin. Ethambutol has been called a poor choice for a first-line treatment for TBM 
due to its poor penetration capacity and the adverse effect of optic neuritis (Donald et al., 
1998). The summarized information shows that ethambutol resistance is less likely to occur 
when it is used as a first-line agent for TBM treatment. However, the low resistance level 
may be a result of poor exposure between the drug and the pathogen. 
Compared to other countries, Thailand has the second-highest drug-resistance rate for TBM 
(table 2). The trend for drug-resistant TBM in Thailand has been previously analyzed; it was 
found that a 3% incidence of MDR-TBM in the first period increased into a 12% incidence in 
the third period (Faksri et al., 2011a). Information regarding the trends of drug resistance in 
other regions is unknown. Nevertheless, it is more likely that drug resistance is 
underestimated, which indicates that the incidence of drug-resistant TBM may be 
increasing. Patel et al. reviewed the medical records of TBM patients from South Africa and 
found that MDR–TBM is a serious problem that has increased the mortality rate up to 57%, 
with the majority of the patients having been treated with anti-tuberculous drugs (Patel et 
al., 2004). Whether or not HIV co-infection and AIDS are involved in the development of 
MDR-TBM, these combined factors result in a marked increase in the difficulty of treatment 
and the mortality rate (Daikos et al., 2003; Patel et al., 2004). This information has raised our 
concerns regarding proper treatment and drug-resistance surveillance for TB and TBM. 
Authors 
Geographical 
regions 
Year of 
collection
Drug resistant profiles (%) 
H R S E MDR Suscep 
1. Yorsangsukkamol et al., 
2009 and Faksri et al., 
2011a 
Thailand (n=184) 1996-2007 20.4 6.1 17.0 5.4 6.1 75.5 
2. Nagarathna et al., 2008 Egypt (n=336) 2001-2005 13 0 0.3 0.2 2.4 82.2 
3. Caws et. al., 2006  Vietnam (n=198) 2000-2003 18.7 3 24.2 0.5 2.5 68.7 
4. Patel et al., 2004  
South Africa 
(n=350) 
1999-2002 NA NA NA NA 8.6 NA 
5. Cooksey et al., 2002 Egypt (n=67) 1998-2000 10.4 1.5 7.5 1.5 0 76.1 
6. Padayatchi et al., 2006  
South Africa 
(n=362) 
1992-2003 NA NA NA NA 2.2 88.4 
7. Girgis et al., 1998  Egypt (n=857) 1976-1996 10 3 0 7 0 80 
8. Karstaedt et al., 1998 
South Africa 
(n=56) 
1994-1997 NA NA NA NA 4.3 NA 
Note: H: isoniazid, R; rifampicin, S: streptomycin, E; ethambutol, MDR: multidrug-resistant, Suscep; 
susceptible to all drugs  
Table 2. Summary of drug-resistant profiles in TBM patients from previous studies 
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5. MTB lineages, TBM and evolution  
The most common pathogen of TB and TBM is MTB. There are a few reports of TBM caused 
by M. bovis (Cooksey et al., 2002; Tardieu et al., 1988). Meningitis can also be caused by 
nontuberculous mycobacteria (NTM) (Huempener et al., 1966). Interestingly, several studies 
have shown different pathogenicities, determined by clinical analysis among MTB lineages 
(Ganiem et al., 2009; Lan et al., 2003; Kong et al., 2007). Studies in animal models (Manca et 
al., 2001; Reed at el., 2004) and macrophage cell lines (Li et al., 2002; Lopez et al., 2003) have 
also indicated that the Beijing genotype of MTB is the most virulent genotype. Furthermore, 
this genotype is also associated with drug resistance, especially MDR (Drobniewski et al., 
2005). It has been hypothesized that this genotype is an escape mutant of the BCG vaccine 
(van Soolingen et al., 1995). Six lineages of MTB have defined names according to specific 
markers based on large sequence polymorphisms (i.e., regions of difference) and 
geographical regions: East Asian (Beijing), Euro American (EuA), East African Indian (EAI), 
Indo-Oceanic (IO), West African I (WA I) and West African II (WA II). 
5.1 TBM and the variation of MTB lineages  
For TBM, the Beijing lineage is also suggested to be the most neurovirulent genotype. The 
most predominant genotype of TBM in Thailand is the Beijing (East Asian) genotype, with 
an incidence of 58%. The Indo-Oceanic (34%) and Euro-American lineages (10%) are the 
second most and least predominant genotypes (Faksri et al., 2011a). MTB lineages found in 
TBM may associate with the lineages that are found in pulmonary TB. However, the 
proportions of lineages may not be the same. More than half of MTB from TBM patients 
were the Beijing genotype (Yorsangsukkamol et al., 2009), whereas only approximately 20% 
of MTB from pulmonary TB were the Beijing genotype (Rienthong et al., 2005). The 
proportion of MTB lineages in TBM patients in Thailand is roughly concordant with TBM 
strains from Vietnam, in which the Beijing (42%) and Indo-Oceanic lineages (44%) are in 
higher proportions; the Euro-American lineage (14%) is the least prevalent. Studies 
conducted in Vietnam suggest that Beijing MTB is the most virulent genotype that causes 
TBM, based on correlation analysis with clinical features. They found that the Beijing lineage 
showed associations with a shorter duration of illness before presentation and drug 
resistance (i.e., the influence of disease progression, intracerebral alteration of inflammatory 
responses and difficulty of treatment) (Thwaites et al., 2008). In Thailand, the predominance 
of the Beijing lineage revealed associations with MDR-TB, a trend that is increasing in 
proportion; additionally, it had the highest clustered rate, supporting its virulence for 
causing TBM. Inversely, the Euro-American lineage has been thought to be the attenuated 
lineage, causing the lowest proportions of TBM, with a decreasing trend of proportion and 
lacking cluster formation (Faksri et al., 2011a). RFLP pattern analysis of CNS–MTB strains 
also suggested that the occurrence of CNS TB might be strain-dependent (Cooksey et al., 
2002; Arvanitakis et al., 1998). Nevertheless, the absence of an association between MTB 
genotypes and the clinical presentation and outcome of TBM has also been described. The 
most predominant strain in this study was not the Beijing genotype (principal genetic group 
1, or PGG 1) of MTB. They found that all 3 PGGs were represented (group 1, 27.1%; group 2, 
59.3%; group 3, 13.6%) (Maree et al., 2007). This information may indicate the variations in 
capacities for causing neurovirulence and TBM among MTB lineages. 
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In addition, variations in virulence within the Beijing family of MTB have been proposed 
(Alonso et al., 2010; Faksri et al., 2011b; Hanekom et al., 2007; Iwamoto et al., 2009; Kong et al., 
2007; Theus et al., 2007). Particular sublineages of the Beijing family of MTB seem to be more 
virulent based on associations with drug resistance and MDR (Twamoto et al., 2008; 
Mokrousov et al., 2006) and exhibit greater transmissibility (Wada et al., 2009). The genetic 
analysis of the Beijing family of MTB isolates based on SNPs, LSPs, IS6110 and VNTR 
profiles from Thailand revealed interesting genetic polymorphisms among Beijing strains. 
While the SNPs showed good correlations with other genetic markers, such as LSPs and 
IS6110, some SNPs may not be irreversible genetic events (i.e., they may occur repeatedly in 
phylogeny). A determination of the variation of virulence of the Beijing sublineages based 
on a combination of genetic markers has been conducted. The results demonstrated 
associations between Beijing sublineages based on phylogeny and virulence, with the 
modern Beijing lineage being more virulent than the ancestral strain (Kaksri et al. 
unpublished). The modern Beijing strain has an increasing trend toward causing TBM in 
Thailand than the ancestral Beijing strain in Thailand (Faksri et al., 2011b). The differences in 
transmissibility based on cluster analysis and the increasing trend of proportion in TBM 
patients compared to the ancestral Beijing sublineage support this hypothesis.  
5.2 Host variation and development of TBM  
Certain host groups seem to be susceptible to TB infection. There are several studies that 
indicate the association of host genetic vitiation and pulmonary TB. For instance, the 
polymorphisms of genes that are involved with cytokines and chemokines showed 
associations with the susceptibility of TB, such as IFN-gamma (Hashemi et al., 2011), TNF-
alpha (Fan et al., 2010), CXCL-10 (Tang et al., 2009), CCL5 (Sanchez-Castanon et al., 2009) and 
SLC11A1 or NRAMP1 (Bellamy et al., 1998). Genome-wide SNP-based linkage analysis in TB 
cases in Thailand showed particular regions, such as 5q, 17p and 20p, on chromosomes 
associated with TB susceptibility (Mahasirimongkol et al., 2009). Other examples of genetic 
polymorphisms and susceptibility to TB are the MC3R promoter, the CTSZ 3'UTR (Adams et 
al., 2011), P2X7 (Xiao et al., 2010) and MMP-9 (Lee et al., 2009). Notably, MMP-9 is the 
enzyme that may be involved in BBB permeability. The variation in MMP-9 encoding gene 
may also be associated with the development of TBM. The origin countries of patients are 
associated with the development of TBM (Bidstrup et al, 2002). The association between host 
genetic variations and susceptibility to the development of TBM has been proposed. SNPs at 
genes encoding Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) 
(Dissanayeke et al., 2009) and Toll-like receptor-2 (TLR-2) have been shown to be associated 
with TB caused by the East Asian (Beijing) lineage of MTB (Thuong et al., 2007), which 
indicates an association between host variation, the preference of certain strains of MTB and 
the development of certain disease types.  
5.3 Co-evolution between MTB and the host in TBM 
In terms of evolution, MTB is regarded as a young pathogen, which means that its 
evolutionary process has occurred relatively recently. MTB underwent an evolutionary 
bottleneck and was derived from the most recent common ancestor (MRCA) approximately 
15,000-30,000 years ago (Gibbons, 2008; Kapur, 1994; Hughes et al., 2002; Wirth et al., 2008). 
Inversely, MTB may have infected humans for hundreds of thousands of years, or longer, 
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before the MRCA appeared (Smith et al., 2009). The nature of this pathogen includes an 
intracellular lifestyle. Humans are always a definite host of MTB. Nevertheless, infection 
caused by MTB can also be found in some animals, such as non-human primates (Corcoran 
and Thoen, 1991) and elephants (Angkawanish et al., 2010; Murphree et al., 2009). Although 
the natural defense mechanism of the host is the elimination of pathogens and foreign 
agents mediated by immune responses, co-adaptation between host and pathogen also 
occurs in nature. A good classical model of co-evolution between humans and bacteria 
involves the hypothesis that mitochondria used to be bacteria that co-adapted to live within 
eukaryotic cells as organelles (Henze and Martin, 2003). A similar model has been posited 
involving chloroplasts or plastids of plant cells (Patrick, 2004). A more obvious co-
adaptation of bacteria to human hosts is the Escherichia coli found in the human 
gastrointestinal tract. The co-evolution between MTB and human hosts may have occurred 
several hundreds of thousands of years ago. However, the pathogens try to survive within 
the host by avoiding or suppressing the host immune response. Latent TB may be the result 
of a co-adaptation between MTB and host immune responses. 
Regarding TBM, MTB is an obligate aerobe and prefers oxygen for growth. The underlying 
reason for this may reflect a preference of MTB to spread to other tissues that contain a high 
oxygen content, including the brain. As evidence of this, lung lesions usually occur in the right 
upper lobe. The altered capacity to pass the BBB may an evolutionary response for better 
growing conditions. Unlike other body tissues, the CNS and the CSF are parts of the body in 
which the immune system is less strict. The adaptation of the pathogen by escaping from the 
host immune system and passing the BBB for more oxygen may explain the variation of 
virulence and the evolution of MTB-associated TBM. However, TBM is a severe from of TB, 
and the evolution of MTB toward a better capacity to enter the CNS, eventually causing the 
death of the host, in turn causing its own death, seems to conflict with an adaptive 
evolutionary response. Further studies are certainly needed to explore this possibility.  
6. Future research topics for TBM 
The neurovirulence of MTB is still unknown. The virulence determinants of the causative 
agent of TBM can contribute to clinical intervention. The lineage-dependent virulence of 
MTB is also interesting to study, especially when applied to the consequences of treatment 
and vaccination. It is worthwhile to note that certain MTB strains may have specific 
properties that facilitate meningeal involvement and result in neurotropism, as found in M. 
leprae, which predispose it to infect peripheral nerves. Information in our unpublished study 
shows that certain MTB strains that vary in the copy numbers of variable number tandem 
repeats (VNTR2163A and 2163B) are associated with TBM rather than pulmonary TB. 
Further studies are needed to confirm this finding. 
The pathogenesis of TBM is mainly based on studies that were performed many decades 
ago. The use of animal models, which are mostly based on rabbits and mice, limit the 
validity of the results. There is a need for appropriate animal models, such as non-human 
primates, for experiments that better reflect human TBM and that may reveal novel 
knowledge regarding pathogenesis and treatment for TBM and TB. Cynomolgus monkeys 
(Walsh et al., 1996) and pigs (Bolin et al., 1997) developed TBM with similar pathologic 
characteristics to human TBM following intratracheal or intravenous inoculation of 
mycobacteria. The mouse model is not a good animal model for TBM study due to its 
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immunological response against infection and granuloma formation. However, because of 
its ease of use and the availability of facilities, mouse models are still practical to use as 
animal models for studying TBM. An attempt to modify the mouse model to provide the 
immunological inflammatory response of TBM is an applicable approach (van Well et al., 
2007). Other aspects of the pathogenesis of TBM can help identify novel interventions. The 
mechanism by which the pathogen spreads hematogenously from the lung or other infected 
organs into the CNS is unknown. The roles of some cytokines, such as MMP-9, vascular 
endothelial growth factor (VEGF) and TNF-α, for controlling the breakdown and 
permeability of the BBB and the role of cell death mechanisms in the pathogenesis of TBM, 
such as apoptosis and autophagy, are included in the list of unanswered questions. The 
implications of the findings from these studies will help to improve the treatment and 
intervention of not only TBM but also other extrapulmonary TB diseases. 
The improvement of molecular methods and strategies to gain more sensitivity and 
specificity can largely aid the diagnosis of TBM. The development of a rapid diagnostic 
method with high sensitivity and specificity that is appropriate for LMIC is also a challenge. 
Furthermore, the rapid diagnosis of drug-resistant TB and TBM will facilitate the treatment 
and management of TBM patients and drug resistance surveillance. 
The development of new effective treatments and novel drugs, especially drugs that can 
effectively penetrate the BBB, is challenging. The role of adjunctive corticosteroids in TBM 
patients co-infected with HIV and the effects or relationships involved in HIV-MTB co-
infection, particularly the aspects of promoting effects of HIV infection and the development 
of MDR-TBM, are also important to study. Developing a rapid method for detection of drug-
resistant strains (especially for MDR- and XDR-TB) in TBM can promote good prognoses and 
positive outcomes. A few studies have shown that bacteriophages can increase the sensitivity 
of detecting MTB in the CSF by using a fluorescent signal that can be detected within a few 
days rather than weeks, as in conventional culture techniques (Jacobs 1993; Drobniewski 1997). 
The improvement of the reliability and the standardization of these diagnosis methods may 
improve the phenotypic-based drug susceptibility testing of MTB. Whether there is a 
protective effect against the severe form of TB (i.e., TBM) and determining the immunological 
role of BCG vaccination against TBM are also important topics to address. 
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